GSK Unveils Promising Results for B7 Drug Data

GSK Unveils Promising Results for B7 Drug Data

GSK plc has announced significant progress in its clinical research with mocertatug rezetecan (Mo-Rez), an innovative antibody-drug conjugate. The drug targets the B7-H4 antigen and has shown promising results in the BEHOLD-1 global phase I clinical trial.

Key Findings from the BEHOLD-1 Study

The BEHOLD-1 trial focused on patients with platinum-resistant ovarian cancer (PROC) and recurrent or advanced endometrial cancer (EC). At the highest dosages tested, Mo-Rez achieved:

  • 62% confirmed objective response rate (cORR) in PROC.
  • 67% cORR in recurrent or advanced EC.

The study demonstrated these results at doses of 5.8 mg/kg for PROC (21 of 34 patients responding, 95% confidence interval: 44-78) and 4.8 mg/kg for EC (8 of 12 patients responding, 95% confidence interval: 35-90).

Clinical Implications

These findings hold particular relevance given the limited treatment options currently available for these cancer types. The B7-H4 antigen is largely expressed in gynecological cancers, offering a targeted approach with potential precision therapy benefits.

As a result of these positive outcomes, GSK plans to initiate five pivotal phase III clinical trials starting in 2026. These trials will further investigate Mo-Rez’s effectiveness in both PROC and endometrial cancers, including evaluations in earlier treatment lines.

Safety and Tolerability Observations

The trial also monitored safety measures. At high doses, treatment-related adverse events (TRAE) led to:

  • 0% discontinuation rate in PROC patients due to TRAE.
  • 4% discontinuation rate in EC patients due to TRAE.

Nausea was the most frequently reported TRAE, affecting 82% of PROC patients and 75% of EC patients. The incidence of serious grade ≥3 TRAEs was observed in 64% of PROC patients and 54% of EC patients, primarily related to hematologic issues.

Future of Mo-Rez in Cancer Treatment

The BEHOLD clinical program, which includes the BEHOLD-1 and an ongoing BEHOLD-2 combination study, demonstrates GSK’s commitment to developing new therapies for challenging cancers. The planned phase III trials will aim to assess Mo-Rez in broader contexts, including:

  • Platinum-sensitive ovarian cancer.
  • First-line maintenance in ovarian cancer.
  • Mismatch-repair proficient endometrial cancer.

As GSK advances with its global development plan, it continues to focus on enhancing treatment options for patients with gynecologic malignancies.

About GSK

GSK is a leading biopharmaceutical company devoted to the innovation of healthcare solutions. With a focus on advancing oncology and other significant health issues, GSK aims to improve patient outcomes worldwide.

For more updates on GSK’s developments in oncology and other areas, visit Filmogaz.com.